For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

The head of Ozempic manufacturer Novo Nordisk on Tuesday defended the high price of the company’s highly sought-after obesity and Type 2 diabetes drugs, blaming pharma middlemen ...

Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

GLP-1 weight-loss drugs alleviate obesity as well as provide other health benefits. Yet they are also the focus of ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

We recently published a list of 10 Best Foreign Stocks To Buy Now. In this article, we are going to take a look at where Novo ...

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

The CEO of Novo Nordisk took questions for more than two hours during a Senate Health Committee hearing focused on addressing ...

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised ...